Dialysis patients may get safer dosing for common infection drug

NCT ID NCT06093269

Ongoing Knowledge-focused Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how the antibiotic cefazolin behaves in the blood of people on chronic hemodialysis who have catheter infections. Researchers will take blood samples at different times to measure drug levels. The goal is to find the best dose to treat infections while avoiding side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cefazolin
What this could lead to: If successful, this could help doctors give the right dose of cefazolin to hemodialysis patients, improving infection treatment and reducing side effects.
What could go wrong: This is a small, early-phase study with only 32 participants, so results may not apply to all patients. It focuses on drug levels, not direct treatment outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BACTEREMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

bacterial infectious disease bacterial infectious disease with sepsis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMODIALYSIS CATHETER INFECTION INFECTION, BACTERIAL

Contacts and locations

Locations

Department of hemodialysis, University Hospital of Tours

Orléans, 45100, France
Department of hemodialysis, University Hospital of Tours

Tours, 37044, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.